Research Use Only
All products are intended solely for laboratory research and are not for human or animal consumption. By purchasing, the buyer agrees to use these products in compliance with all applicable laws.
CJC-1295 with DAC is a synthetic 30-amino-acid peptide. It was originally derived from the first 29 residues of growth hormone-releasing hormone (GHRH), modified at four positions and conjugated to a Drug Affinity Complex (DAC) that binds serum albumin. Since its development in the early 2000s, CJC-1295 with DAC has been studied extensively in controlled experimental settings for its potential influence on GHRH-receptor signaling, growth hormone secretion, and IGF-1 dynamics.
Jetté L. et al. (2005).
The peptide was first developed by ConjuChem Biotechnologies as a long-acting analog of GHRH, which is otherwise cleaved within minutes in circulation. Early experiments focused on the DAC modification, a maleimidopropionyl group that covalently binds albumin and extends the compound's plasma half-life to several days. Over time, studies broadened into endocrine, metabolic, and systemic systems, where CJC-1295 with DAC consistently demonstrated properties of interest in the context of sustained growth hormone release and biological resilience.
Teichman S.L. et al. (2006).
CJC-1295 with DAC Structure
CAS #: 863288-34-0
Molecular Formula: C₁₆₅H₂₆₉N₄₇O₄₆
Molecular Weight: 3647.15 g/mol
PubChem ID: 91971820
CJC-1295 with DAC has been studied in endocrine, metabolic, pharmacokinetic, and systemic models, with reports of activity in GHRH-receptor activation, pulsatile growth hormone secretion, IGF-1 elevation, and albumin-mediated half-life extension. Research also highlights signaling roles in preclinical systems, supporting cellular integrity and pathway dynamics. Key Areas of Research:
Endocrine: GHRH receptor, GH secretion, pituitary
Metabolic: IGF-1 axis, protein synthesis, adiposity
Pharmacokinetic: Albumin binding, half-life, DPP-IV resistance
Systemic: Signaling, tissue models, pathway dynamics
Together, these findings suggest broad experimental utility for CJC-1295 with DAC across multiple biological pathways. Its activity in endocrine, metabolic, and systemic models provides a foundation for exploring diverse aspects of molecular biology. By influencing processes such as growth hormone secretion, receptor activation, and molecular signaling, CJC-1295 with DAC offers a versatile platform for research into pathway dynamics and systemic resilience within experimental settings.
Ionescu M., Frohman L.A., Journal of Clinical Endocrinology & Metabolism, 2006
References
Jetté L. et al. (2005). Identification of CJC-1295 as a long-lasting GRF analog: hGRF(1-29)-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats.
Teichman S.L. et al. (2006). Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults.
Ionescu M., Frohman L.A. (2006). Pulsatile growth hormone secretion persists during continuous stimulation by CJC-1295, a long-acting GHRH analog.
Our Process
Text us, our dedicated team is here to help
Frequently Asked Questions
Everything you need to know about our products and processes.
What's the actual amount in each vial?
Are additional supplies needed?
How long does a vial last?
Does the product come with instructions?
What purity level is guaranteed?
How should I store these products?
